Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
Joint Authors
Nassar, Amr
Elgohary, Ghada
Elhassan, Tusneem
Nurgat, Zubeir
Mohamed, Said Y.
Aljurf, Mahmoud
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-10-27
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Glucocorticoids have been the primary treatment of graft-versus-host disease (GVHD) over the past decade.
Complete responses to steroid therapy are usually expected in almost one-third of aGVHD cases and partial response is anticipated in another one-third of patients.
However, for those patients not responding to corticosteroid treatment, there is no standard second-line therapy for acute or chronic GVHD.
Methotrexate (MTX) for treatment of steroid refractory GVHD has been evaluated in a number of studies.
Results from peer-reviewed original articles were identified and the pooled data analyzed.
Despite several limitations in data collection and analysis, weekly administration of methotrexate at a median dose of 7.5 mg/m2 seems to be safe with minimal toxicities in the context of both aGVHD and cGVHD treatments.
The observed overall response (OR) in patients with aGVHD to MTX treatment in the published studies was 69.9%, with complete response (CR) in 59.2% and PR in 10.6%.
In cGVHD the OR was 77.6%, with CR reported in 49.6% and PR in 28% of patients.
Predictors of better responses were lower grade GVHD, cutaneous involvement, and isolated organ involvement.
MTX as a steroid sparing agent might reduce long-term complications and improve the quality of life of GVHD affected individuals.
American Psychological Association (APA)
Nassar, Amr& Elgohary, Ghada& Elhassan, Tusneem& Nurgat, Zubeir& Mohamed, Said Y.& Aljurf, Mahmoud. 2014. Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Transplantation،Vol. 2014, no. 2014, pp.1-10.
https://search.emarefa.net/detail/BIM-1043302
Modern Language Association (MLA)
Nassar, Amr…[et al.]. Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Transplantation No. 2014 (2014), pp.1-10.
https://search.emarefa.net/detail/BIM-1043302
American Medical Association (AMA)
Nassar, Amr& Elgohary, Ghada& Elhassan, Tusneem& Nurgat, Zubeir& Mohamed, Said Y.& Aljurf, Mahmoud. Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Transplantation. 2014. Vol. 2014, no. 2014, pp.1-10.
https://search.emarefa.net/detail/BIM-1043302
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1043302